L Lashnews Medical aesthetics sourcing from China
News Sourcing Guide

【South Korea】Jeisys Medical’s DENSITY Surpasses 1,000 Units Shipped Domestically Within 3 Years of Launch

Editor’s Note

**Editor’s Note:** Jeisys Medical’s DENSITY device has reached a significant milestone, surpassing 1,000 units shipped domestically within three years of its launch. This achievement underscores the rising demand for non-invasive aesthetic procedures in South Korea.

BIO Insight

Jeisys Medical announced on the 24th that its flagship radiofrequency (RF) medical device, DENSITY, surpassed 1,000 units shipped domestically as of June 2026. Since its launch in April 2023, DENSITY has maintained a steady increase in shipments. This achievement marks a milestone for a single country within approximately three years of launch. The growing interest from medical professionals and patients in non-invasive skin aesthetic procedures is interpreted as a key driver behind DENSITY’s consistent shipment growth.

Product Line Expansion

In particular, the expansion of DENSITY’s product lineup has also drawn attention alongside this achievement. The third-generation new tip for DENSITY, ‘Alpha Tip’, launched in January, recorded cumulative supply of 10,000 units within three months and 20,000 units within four months, with shipments continuing to expand thereafter. The DENSITY Alpha Tip is a third-generation tip designed exclusively for DENSITY, supporting both monopolar and bipolar RF energy delivery methods. It features an expanded electrode area compared to previous tips.

This milestone of 1,000 units for DENSITY is the result of sustained growth since its launch, and Jeisys Medical considers it a meaningful landmark.

“The domestic shipment of 1,000 units of DENSITY is the outcome of the trust and continuous interest built within the industry, combined with steady growth since its launch,” said a Jeisys Medical representative. “Going forward, we will actively expand our brand influence in the global and domestic aesthetic medical device market through the expansion of new lineups, including the Alpha Tip, to continue our growth.”
HLB “리라푸그라티닙, FDA 후반부 심사서 특별한 이견 없어”
Full article: View original |
⏰ Published on: July 24, 2026